Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04794699 · ClinicalTrials.gov registry record · Phase 1
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
A Phase 1 study of Solid Tumor, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT04794699 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 180 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04794699, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Sacituzumab govitecan
- DRUG Paclitaxel
- DRUG IDE397
Study Locations (20)
California
- City of Hope - Duarte
- Hoag Memorial Hospital - Newport Beach
- Providence Medical Group - Santa Rosa
Florida
- Advent Health - Celebration
- Orlando Health Cancer Institute - Orlando
New York
- Columbia University Medical Center - Herbert Irving Pavilion - New York
- Weill Cornell Medical College - New York
Texas
- MD Anderson - Houston
- Next Oncology - San Antonio
Arizona
- Honor Health Research Institute - Scottsdale
Arkansas
- Rockefeller Cancer Institute - Little Rock
Indiana
- Indiana University Health Hospital - Indianapolis
Kentucky
- Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04794699
The ClinicalTrials.gov registry entry for NCT04794699 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (19% lower). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT04794699 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04794699 about?
NCT04794699 is a clinical study titled "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion". This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult pa...
What is the current status of trial NCT04794699?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2021-04-14. Estimated completion is 2027-03-30.
What conditions does trial NCT04794699 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT04794699?
The interventions under investigation include: Docetaxel (DRUG), Sacituzumab govitecan (DRUG), Paclitaxel (DRUG), IDE397 (DRUG).
Who is sponsoring clinical trial NCT04794699?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04794699 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.